Patents-Review.com
ClassID:

109200 ⎘

C12N2310/3521 - CPC Classification

Classification description:

Structure or type of the nucleic acid; Chemical structure; Nature of the modification linked to the nucleic acid via a carbon atom Methyl

Recent Application in this class:
#1
20260092283
2026-04-02

COMPOSITIONS AND METHODS FOR THE TREATMENT OF COMPLICATIONS AND DISORDERS RELATING TO VON WILLEBRAND FACTOR

 #2
20260053839
2026-02-26

COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS

 #3
20260035703
2026-02-05

Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping

 #4
20250333737
2025-10-30

17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #5
20250320494
2025-10-16

INHIBITORS OF EXPRESSION AND/OR FUNCTION

 #6
20250188456
2025-06-12

HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #7
20250152746
2025-05-15

BASE EDITING OF ANGPTL3 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE

 #8
20250145997
2025-05-08

Antisense Nucleic Acids

 #9
20250075215
2025-03-06

COMPOSITIONS AND METHODS FOR MODULATING NEURONAL EXCITABILITY AND MOTOR BEHAVIOR

 #10
20250066784
2025-02-27

THERAPEUTIC OLIGONUCLEOTIDES

 #11
20250034566
2025-01-30

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

 #12
20250017953
2025-01-16

LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #13
20250011784
2025-01-09

RNA MODULATING OLIGONUCLEOTIDES WITH IMPROVED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

 #14
20240417721
2024-12-19

SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES

 #15
20240390523
2024-11-28

BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE

 #16
20240327839
2024-10-03

NOVEL THERAPEUTIC DELIVERY MOIETIES AND USES THEREOF

 #17
20240318171
2024-09-26

CRISPR-BASED COMPOSITIONS AND METHODS OF USE

 #18
20240309387
2024-09-19

TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #19
20240309377
2024-09-19

REDUCING INTRON RETENTION

 #20
20240301428
2024-09-12

COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING

 #21
20240287524
2024-08-29

GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #22
20240255880
2024-08-01

SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT

 #23
20240254486
2024-08-01

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

 #24
20240247271
2024-07-25

RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)

 #25
20240229011
2024-07-11

MODIFIED NUCLEIC ACIDS, HYBRID GUIDE RNAS, AND USES THEREOF

 #26
20240191240
2024-06-13

DEFINED MULTI-CONJUGATES OLIGONUCLEOTIDES

 #27
20240141348
2024-05-02

ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT

 #28
20240141346
2024-05-02

TARGETED INHIBITION USING ENGINEERED OLIGONUCLEOTIDES

 #29
20240117344
2024-04-11

METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF

 #30
20240110180
2024-04-04

COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES

 #31
20240100080
2024-03-28

METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS

 #32
20240075052
2024-03-07

COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN (TTR) MEDIATED AMYLOIDOSIS

 #33
20230383299
2023-11-30

SIRNA, MEDICAL COMPOSITIONS, AND METHODS FOR TREATING DIABETES USING THE SAME

 #34
20230374522
2023-11-23

COMPOSITIONS AND METHODS FOR MODULATING SCAP ACTIVITY

 #35
20230365965
2023-11-16

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #36
20230340435
2023-10-26

Base editing of ANGPTL3 and methods of using same for treatment of disease

 #37
20230295626
2023-09-21

Targeted inhibition using engineered oligonucleotides

 #38
20230279392
2023-09-07

Single-stranded RNA-editing oligonucleotides

 #39
20230250426
2023-08-10

METHOD FOR TREATING AND PROGNOSING CANCER LIKE GLIOBLASTOMA

 #40
20230183693
2023-06-15

Reducing intron retention

 #41
20230167452
2023-06-01

COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING

 #42
20230159926
2023-05-25

Base editing of PCSK9 and methods of using same for treatment of disease

 #43
20230147979
2023-05-11

DESIGN METHOD FOR OPTIMIZED RIG-I LIGANDS

 #44
20230132602
2023-05-04

Targeted Inhibition Using Engineered Oligonucleotides

 #45
20230030119
2023-02-02

RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)

 #46
20220403382
2022-12-22

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

 #47
20220333114
2022-10-20

SiRNA, medical compositions, and methods for treating type ii diabetes using the same

 #48
20220290148
2022-09-15

Defined multi-conjugates oligonucleotides

 #49
20220275386
2022-09-01

Methods and compositions for targeting RNA polymerases and non-coding RNA biogenesis to specific loci

 #50
20220213480
2022-07-07

Targeted inhibition using engineered oligonucleotides

 #51
20220202847
2022-06-30

HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #52
20220162604
2022-05-26

ANTISENSE NUCLEIC ACIDS

 #53
20220155716
2022-05-19

SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT

 #54
20220127610
2022-04-28

OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA

 #55
20220119820
2022-04-21

COMPOSITIONS AND METHODS FOR CORRECTING LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2C USING EXON SKIPPING

 #56
20220090091
2022-03-24

COMPOSITIONS OF POLYNUCLEIC ACID VECTORS AND USES THEREOF

 #57
20220073918
2022-03-10

Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat

 #58
20220072029
2022-03-10

Bi specific aptamer

 #59
20220049253
2022-02-17

COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF APOLIPOPROTEIN C-III (APOC3) GENES

 #60
20220049252
2022-02-17

CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF

 #61
20220010310
2022-01-13

An lncRNA integrates a DNA-PK-mediated DNA damage response and vascular senescence

 #62
20210388360
2021-12-16

COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF PROTEIN C (PROC) GENES

 #63
20210380985
2021-12-09

17ß-Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof

 #64
20210361692
2021-11-25

Compositions and methods for treating transthyretin (TTR) mediated amyloidosis

 #65
20210346509
2021-11-11

GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof

 #66
20210340529
2021-11-04

Single-stranded RNA-editing oligonucleotides

 #67
20210317451
2021-10-14

Compositions and methods for modulating neuronal excitability and motor behavior

 #68
20210254076
2021-08-19

TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #69
20210254063
2021-08-19

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #70
20210228614
2021-07-29

LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #71
20210171956
2021-06-10

Glucokinase (GCK) iRNA compositions and methods of use thereof

 #72
20210147849
2021-05-20

REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS

 #73
20210095279
2021-04-01

Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA

 #74
20210087567
2021-03-25

Therapeutic oligonucleotides

 #75
20210087558
2021-03-25

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

 #76
20210062198
2021-03-04

Interfering RNA molecules

 #77
20210041823
2021-02-11

SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT

 #78
20210032631
2021-02-04

Compositions and Methods for Correcting Limb Girdle Muscular Dystrophy Type 2C Using Exon Skipping

 #79
20200392511
2020-12-17

TMPRSS6 iRNA compositions and methods of use thereof

 #80
20200325480
2020-10-15

Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field

 #81
20200308588
2020-10-01

HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #82
20200263176
2020-08-20

Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes

 #83
20200239890
2020-07-30

Compositions and methods for inhibition of expression of protein C (PROC) genes

 #84
20200231969
2020-07-23

Reducing intron retention

 #85
20200216844
2020-07-09

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #86
20200208154
2020-07-02

ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT

 #87
20200206258
2020-07-02

LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #88
20200190511
2020-06-18

MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF

 #89
20200181622
2020-06-11

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

 #90
20200181614
2020-06-11

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

 #91
20200165612
2020-05-28

Compositions and methods for the treatment of complications and disorders relating to Von Willebrand Factor

 #92
20200149043
2020-05-14

RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders

 #93
20200149040
2020-05-14

Antisense nucleic acids

 #94
20200138847
2020-05-07

Myostatin iRNA compositions and methods of use thereof

 #95
20200113927
2020-04-16

LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #96
20200109405
2020-04-09

Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1

 #97
20200109402
2020-04-09

Methods of reducing expression of x-inactivation escapee genes and autosomal genes

 #98
20200056175
2020-02-20

COMPOSITIONS AND METHODS FOR INHIBITIION OF EXPRESSION OF PROTEIN C (PROC) GENES

 #99
20200056167
2020-02-20

Modified nucleic acids, hybrid guide RNAs, and uses thereof

 #100
20200040333
2020-02-06

Compositions and methods for modulating SMN gene family expression

 #101
20200032260
2020-01-30

Compositions and methods for modulation of IKBKAP splicing

 #102
20190390201
2019-12-26

Interfering RNA molecules

 #103
20190382751
2019-12-19

MODIFIED CRISPR RNA AND USES THEREOF

 #104
20190354055
2019-11-21

Serpina1 siRNAs: compositions of matter and methods of treatment

 #105
20190350962
2019-11-21

METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS

 #106
20190343867
2019-11-14

Bi-specific aptamer

 #107
20190330639
2019-10-31

RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)

 #108
20190330622
2019-10-31

Single-stranded RNA-editing oligonucleotides

 #109
20190249180
2019-08-15

Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping

 #110
20190241894
2019-08-08

MOLECULAR RE-ENGINEERING OF EXCITATION-INHIBITION BALANCE IN MEMORY CIRCUITS

 #111
20190218549
2019-07-18

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

 #112
20190211341
2019-07-11

TMPRSS6 iRNA compositions and methods of use thereof

 #113
20190211337
2019-07-11

Neutral nanotransporters

 #114
20190211336
2019-07-11

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

 #115
20190203216
2019-07-04

Methods and compositions for targeting RNA polymerases and non-coding RNA biogenesis to specific loci

 #116
20190161757
2019-05-30

Reduced size self-delivering RNAI compounds

 #117
20190144869
2019-05-16

Allele-specific gene suppression

 #118
20190144858
2019-05-16

Compositions and methods for modulating neuronal excitability and motor behavior

 #119
20190134214
2019-05-09

GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof

 #120
20190106700
2019-04-11

siRNA And Their Use In Methods And Compositions For Inhibiting The Expression Of The ORAI1 Gene

 #121
20190085331
2019-03-21

Defined multi-conjugate oligonucleotides

 #122
20190078091
2019-03-14

Antisense oligonucleotides for the treatment of Leber congenital amaurosis

 #123
20190078090
2019-03-14

DOWNREGULATING MIR-132 FOR THE TREATMENT OF LIPID RELATED DISORDERS

 #124
20190071672
2019-03-07

Pharmaceutical Composition

 #125
20190040385
2019-02-07

Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof

 #126
20190038768
2019-02-07

Modified RNAi agents

 #127
20190038658
2019-02-07

High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof

 #128
20190038538
2019-02-07

RNA complexes that inhibit melanin production

 #129
20190037583
2019-01-31

Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof

 #130
20190032053
2019-01-31

SYNTHETIC GUIDE RNA FOR CRISPR/CAS ACTIVATOR SYSTEMS

 #131
20190024089
2019-01-24

Interfering RNA molecules

 #132
20190017052
2019-01-17

Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease

 #133
20190010502
2019-01-10

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE

 #134
20190002879
2019-01-03

Methods and compositions for the specific inhibition of β-catenin by double-stranded RNA

 #135
20180371464
2018-12-27

RNA interference in dermal and fibrotic indications

 #136
20180371457
2018-12-27

Compositions and methods for modulation of IKBKAP splicing

 #137
20180362978
2018-12-20

Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes

 #138
20180362977
2018-12-20

RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

 #139
20180360866
2018-12-20

MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes

 #140
20180355362
2018-12-13

Organic compositions to treat beta-ENaC-related diseases

 #141
20180355355
2018-12-13

MicroRNA Compounds and Methods for Modulating MIR-21 Activity

 #142
20180346910
2018-12-06

Serpina1 iRNA compositions and methods of use thereof

 #143
20180346906
2018-12-06

Methods of reducing expression of X-inactivation escapee genes and autosomal genes

 #144
20180327748
2018-11-15

RNA interference in skin indications

 #145
20180305696
2018-10-25

METHODS AND COMPOSITIONS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN ORGANS

 #146
20180305692
2018-10-25

Antisense oligonucleotides for the treatment of leber congenital amaurosis

 #147
20180298384
2018-10-18

COMPOSITIONS AND METHODS FOR MODULATING SMN GENE FAMILY EXPRESSION

 #148
20180291381
2018-10-11

Interfering RNA molecules

 #149
20180291379
2018-10-11

Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA

 #150
20180282723
2018-10-04

Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA

 #151
20180273946
2018-09-27

MODULATION OF TRANSTHYRETIN EXPRESSION

 #152
20180265870
2018-09-20

AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

 #153
20180258430
2018-09-13

Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin

 #154
20180237785
2018-08-23

Notch 1 specific siRNA molecule

 #155
20180230473
2018-08-16

Modified TGF-beta oligonucleotides

 #156
20180230470
2018-08-16

Compositions and methods for inhibiting gene expression of Hif2alpha

 #157
20180230468
2018-08-16

Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1

 #158
20180223286
2018-08-09

Interfering RNA molecules

 #159
20180223282
2018-08-09

Compositions and methods for modulating MECP2 expression

 #160
20180223279
2018-08-09

THERAPEUTIC OLIGONUCLEOTIDES

 #161
20180216115
2018-08-02

Compositions and methods for inhibiting expression of the PCSK9 gene

 #162
20180201930
2018-07-19

COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS

 #163
20180195073
2018-07-12

Glucokinase (GCK) iRNA compositions and methods of use thereof

 #164
20180195071
2018-07-12

RNA interference mediated inhibition of hepatitis B Virus (HBV) gene expression using short interfering nucleic acid (siNA)

 #165
20180195062
2018-07-12

Pharmaceutical Composition

 #166
20180179523
2018-06-28

CRISPR-BASED COMPOSITIONS AND METHODS OF USE

 #167
20180171385
2018-06-21

ALKB -FACILITATED RNA METHYLATION SEQUENCING (ARM-SEQ)

 #168
20180163204
2018-06-14

Micro-RNA family that modulates extracellular matrix genes and uses thereof

 #169
20180155723
2018-06-07

Restoration of the CFTR function by splicing modulation

 #170
20180155718
2018-06-07

RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality

 #171
20180153919
2018-06-07

ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES

 #172
20180148726
2018-05-31

RNAi inhibition of alpha-ENaC expression

 #173
20180148723
2018-05-31

Chemical modification of short small hairpin RNAs for inhibition of gene expression

 #174
20180142244
2018-05-24

MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION

 #175
20180135057
2018-05-17

Compositions and methods for inhibiting expression of the LECT2 gene

 #176
20180119152
2018-05-03

Antisense compounds targeting genes associated with cystic fibrosis

 #177
20180105812
2018-04-19

Short interfering nucleic acid (siNA) compositions

 #178
20180094263
2018-04-05

Oligonucleotide compounds for targeting huntingtin mRNA

 #179
20180094262
2018-04-05

Inhibitors of MYH7B and uses thereof

 #180
20180087058
2018-03-29

TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #181
20180087055
2018-03-29

MODIFIED TGF-BETA2 OLIGONUCLEOTIDES

 #182
20180080030
2018-03-22

Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping

 #183
20180080024
2018-03-22

Single-stranded RNAi agents containing an internal, non-nucleic acid spacer

 #184
20180066256
2018-03-08

RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders

 #185
20180066255
2018-03-08

Compositions and methods for inhibition of expression of protein C (PROC) genes

 #186
20180051290
2018-02-22

Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease

 #187
20180051283
2018-02-22

Compositions and methods for modulating Tau expression

 #188
20180044679
2018-02-15

Composition for treating cancer associated with HPV infection

 #189
20180044671
2018-02-15

DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO P53 AND METHODS OF USE THEREOF

 #190
20180037886
2018-02-08

Compositions and methods for inhibiting expression of the ALAS1 gene

 #191
20180030454
2018-02-01

RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)

 #192
20180030450
2018-02-01

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

 #193
20180030446
2018-02-01

APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS

 #194
20180023084
2018-01-25

Disulfide-containing alkyne linking agents

 #195
20180010125
2018-01-11

Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof

 #196
20180002694
2018-01-04

Reducing intron retention

 #197
20170335330
2017-11-23

Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof

 #198
20170327825
2017-11-16

Decoy oligonucleotides for the treatment of diseases

 #199
20170275618
2017-09-28

METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA

 #200
20170268006
2017-09-21

TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF

 #201
20170260531
2017-09-14

Post-selec modification methods

 #202
20170253880
2017-09-07

Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field

 #203
20170247701
2017-08-31

NUCLEIC ACID CAPABLE OF INHIBITING EXPRESSION OF BETA-2GPI

 #204
20170247691
2017-08-31

Interfering RNA molecules

 #205
20170240900
2017-08-24

RAS exon 2 skipping for cancer treatment

 #206
20170218376
2017-08-03

Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1

 #207
20170211071
2017-07-27

Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF

 #208
20170191066
2017-07-06

Antisense compounds targeting apolipoprotein E receptor 2

 #209
20170152515
2017-06-01

Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1

 #210
20160376588
2016-12-29

Molecular re-engineering of excitation-inhibition balance in memory circuits

 #211
20160333342
2016-11-17

Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

 #212
20160333341
2016-11-17

MicroRNA compounds and methods for modulating miR-21 activity

 #213
20160304879
2016-10-20

Double-stranded RNA compounds to CASP2 and uses thereof

 #214
20160304876
2016-10-20

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

 #215
20160264972
2016-09-15

Compositions and Methods for Inhibiting Expression of a Gene from the Ebola Virus

 #216
20160257962
2016-09-08

RNA INTERFERENCE MEDIATED INHIBITION OF ISOCITRATE DEHYDROGENASE (IDH1) GENE EXPRESSION

 #217
20160257954
2016-09-08

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #218
20160244767
2016-08-25

Antisense compounds targeting genes associated with cystic fibrosis

 #219
20160244765
2016-08-25

Reduced size self-delivering RNAI compounds

 #220
20160244757
2016-08-25

Compositions and methods for modulating neuronal excitability and motor behavior

 #221
20160244752
2016-08-25

Serpina1 siRNAs: compositions of matter and methods of treatment

 #222
20160237437
2016-08-18

Toll-like receptor 9 antagonist and methods of use thereof

 #223
20160194638
2016-07-07

Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals

 #224
20160194637
2016-07-07

Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals

 #225
20160177306
2016-06-23

Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field

 #226
20160145629
2016-05-26

TMPRSS6 iRNA compositions and methods of use thereof

 #227
20160145622
2016-05-26

Dengue virus-specific siRNA, double helix oligo-RNA structure comprising siRNA, and composition for suppressing proliferation of dengue virus comprising RNA structure

 #228
20160082122
2016-03-24

Non-immunogenic and nuclease resistant nucleic acid origami devices and compositions thereof

 #229
20160046944
2016-02-18

Aptamer to IL-17 and use thereof

 #230
20160024499
2016-01-28

Compositions and methods for inhibition of expression of protein C (PROC) genes

 #231
20150353930
2015-12-10

Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta

 #232
20150337312
2015-11-26

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

 #233
20150315584
2015-11-05

Compositions and methods for silencing apolipoprotein C-III expression

 #234
20150315582
2015-11-05

Deep intronic target for splicing correction on spinal muscular atrophy gene

 #235
20150299711
2015-10-22

Composition for treating cancer associated with HPV infection

 #236
20150267195
2015-09-24

Oligomeric compounds comprising bicyclic nucleosides and uses thereof

 #237
20150267194
2015-09-24

Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof

 #238
20150211011
2015-07-30

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

 #239
20150203845
2015-07-23

Double-stranded oligonucleotide molecules to P53 and methods of use thereof

 #240
20150159160
2015-06-11

Compositions and methods for modulating ATP2A2 expression

 #241
20150148404
2015-05-28

RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders

 #242
20150125516
2015-05-07

Transferrin receptor aptamers and aptamer-targeted delivery

 #243
20150017163
2015-01-15

Methods for Treating or Preventing Ophthalmological Conditions

 #244
20140371439
2014-12-18

Double-stranded RNA compounds to CASP2 and uses thereof

 #245
20140343122
2014-11-20

Compositions and methods for inhibiting expression of factor VII gene

 #246
20140335605
2014-11-13

Anti-microRNA oligonucleotide molecules

 #247
20140316121
2014-10-23

Methods and compounds useful in conditions related to repeat expansion

 #248
20140275222
2014-09-18

Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof

 #249
20140248338
2014-09-04

Compositions and methods for silencing aldehyde dehydrogenase

 #250
20140243394
2014-08-28

Compositions and methods for inhibiting expression of a gene from the Ebola virus

 #251
20140142162
2014-05-22

Compositions and methods for inhibition of expression of protein C (PROC) genes

 #252
20140127325
2014-05-08

Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression

 #253
20140113957
2014-04-24

Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

 #254
20140031537
2014-01-30

Oligonucleotides for modulation of target RNA activity

 #255
20130296402
2013-11-07

Base modified oligonucleotides

 #256
20130065943
2013-03-14

Compositions and methods for inhibiting expression of CD45 gene

 #257
20130039895
2013-02-14

miR-150 for the treatment of blood disorders

 #258
20130035369
2013-02-07

DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION

 #259
20130028889
2013-01-31

DOSING REGIMENS FOR TREATING AND PREVENTING OCULAR DISORDERS USING C-RAF ANTISENSE

 #260
20130023580
2013-01-24

Compositions and methods for inhibiting expression of XBP-1 gene

 #261
20130023579
2013-01-24

Modulation of angiopoietin-like 3 expression

 #262
20130023577
2013-01-24

Compositions and methods for inhibiting expression of Eg5 and VEGF genes

 #263
20130018084
2013-01-17

MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes

 #264
20130018082
2013-01-17

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

 #265
20130012572
2013-01-10

Compositions and methods for inhibiting expression of GSK-3 genes

 #266
20130012571
2013-01-10

Organic compositions to treat Beta-ENaC-related diseases

 #267
20130012570
2013-01-10

GNAQ targeted dsRNA compositions and methods for inhibiting expression

 #268
20130012567
2013-01-10

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

 #269
20130005793
2013-01-03

Compositions and methods for inhibiting gene expression of hepatitis B virus

 #270
20120329856
2012-12-27

Methods and compositions for reducing viral genome amounts in a target cell

 #271
20120322991
2012-12-20

Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types

 #272
20120322860
2012-12-20

Aptamer therapeutics useful in the treatment of complement-related disorders

 #273
20120322855
2012-12-20

Duplex oligonucleotide complexes and methods for gene silencing by RNA interference

 #274
20120321700
2012-12-20

Compositions and methods for inhibiting expression of the HAMP gene

 #275
20120295963
2012-11-22

AGENTS, COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIES IN WHICH REGULATING AN ACHE-ASSOCIATED BIOLOGICAL PATHWAY IS BENEFICIAL

 #276
20120294905
2012-11-22

Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)

 #277
20120288933
2012-11-15

Synthetic mimics of miR-34

 #278
20120283312
2012-11-08

Modulation of eIF4E expression

 #279
20120277284
2012-11-01

Modulation of signal transducer and activator of transcription 3 (STAT3)expression

 #280
20120277163
2012-11-01

MicroRNA-10 antagonists and MicroRNA-10 targets for use in the treatment of a glioma

 #281
20120276627
2012-11-01

Synthetic mimics of MIR-124

 #282
20120270925
2012-10-25

Antisense molecules and methods for treating pathologies

 #283
20120259001
2012-10-11

Duplex oligonucleotides with enhanced functionality in gene regulation

 #284
20120258104
2012-10-11

Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes

 #285
20120252880
2012-10-04

Oligonucleotide complex compositions and methods of use as gene alteration tools

 #286
20120252872
2012-10-04

RNAi modulation of APOB and uses thereof

 #287
20120245219
2012-09-27

Minor groove binder (MGB)-oligonucleotide miRNA antagonists

 #288
20120238618
2012-09-20

Antisense oligonucleotides for inhibition of microRNA-21

 #289
20120232124
2012-09-13

Compositions and methods for prognosis and treatment of prostate cancer

 #290
20120225927
2012-09-06

Compositions and methods for inhibiting expression of transthyretin

 #291
20120225034
2012-09-06

AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY

 #292
20120220761
2012-08-30

Process for triphosphate oligonucleotide synthesis

 #293
20120220649
2012-08-30

MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE

 #294
20120208864
2012-08-16

COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR

 #295
20120208860
2012-08-16

Compositions and methods for inhibiting expression of factor VII gene

 #296
20120207818
2012-08-16

COMPOSITION FOR SUPPRESSING EXPRESSION OF TARGET GENE

 #297
20120202752
2012-08-09

Antisense oligonucleotides

 #298
20120196920
2012-08-02

ANTISENSE OLIGONUCLEOTIDES AGAINST ACETYLCHOLINESTERASE FOR TREATING INFLAMMATORY DISEASES

 #299
20120184601
2012-07-19

ANTIVIRAL OLIGONUCLEOTIDES

 #300
20120184595
2012-07-19

Compositions and methods for silencing apolipoprotein C-III expression